Literature DB >> 7067210

Use of the Giliberty bipolar endoprosthesis in femoral neck fractures.

G S Bhuller.   

Abstract

Thirty-three patients (average age, 78.9 years) with femoral neck fractures were treated with Giliberty bipolar prosthesis inserted through a posterior approach. There were four procedure-related deaths. Nine patients required readmission for treatment of complications including five patients with a dislocated prosthesis and two with a disassembled prosthesis. The average hospital stay was 30.2 days. Varus position of the cup is a possible cause of component disassembly. This prosthesis is probably unsuitable in the elderly patient with a femoral neck fracture.

Entities:  

Mesh:

Year:  1982        PMID: 7067210

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  5 in total

1.  Is the dislocation rate higher after bipolar hemiarthroplasty in patients with neuromuscular diseases?

Authors:  Kuen Tak Suh; Dae Woong Kim; Hong Seok Lee; Yoon Jae Seong; Jung Sub Lee
Journal:  Clin Orthop Relat Res       Date:  2011-10-21       Impact factor: 4.176

2.  Risk Factors Associated with Dislocation after Bipolar Hemiarthroplasty in Elderly Patients with Femoral Neck Fracture.

Authors:  Yeesuk Kim; Joon-Kuk Kim; Il-Han Joo; Kyu-Tae Hwang; Young-Ho Kim
Journal:  Hip Pelvis       Date:  2016-06-30

3.  The Monk Hard-Top prosthesis for displaced intracapsular fractures of the femoral neck.

Authors:  H B Casserly; B Healy
Journal:  Ir J Med Sci       Date:  1991-01       Impact factor: 1.568

4.  Treatment of secondary osteoarthritis and rheumatoid arthritis by Bateman hip prosthesis.

Authors:  T Torisu; H Morita; H Tsumura
Journal:  Arch Orthop Trauma Surg       Date:  1986

5.  Five cases of early dissociation between the bipolar hip endoprosthesis cup components; either spontaneously or during reduction maneuvers.

Authors:  Vedat Uruç; Raif Özden; İbrahim Gökhan Duman; Aydıner Kalacı
Journal:  Acta Orthop Traumatol Turc       Date:  2017-02-21       Impact factor: 1.511

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.